Atrosimab
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01938599)
Timeline
Indications
Mechanism of action
- Tumor necrosis factor receptor R1INHIBITOR
TNFRSF1A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- am001
- am001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04650126 | Phase 1 | Jul 12, 2021 | Baliopharm Pty Ltd, Q-Pharm |
| NCT03210740 | Phase 2 | Jun 6, 2017 | AmDerma |
| NCT03005964 | Phase 2 | Dec 1, 2016 | AmDerma, International Dermatology Research Inc. |
| NCT01938599 | Phase 2 | Aug 1, 2013 | AmDerma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AmDerma | For profit | 3 | 3 | 1 | 2013 |
| Baliopharm Pty Ltd | Academic/Hospital | 1 | 1 | 1 | 2021 |
| International Dermatology Research Inc. | For profit | 1 | 0 | 1 | 2016 |
| Q-Pharm | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1